



# BAL PHARMA LIMITED

## Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,  
Palace Road, Bangalore - 560 052, India.

To,  
The Manager-Listing  
National Stock Exchange of India Ltd  
Mumbai.

09.02.2026

BSE Limited  
Mumbai.

Dear Sir,

Sub : Results of postal ballot notice dated 30.06.2025.  
Ref : Regulation 44(3) of SEBI (LODR) Regulations, 2015.

With reference to the above cited subject and reference and further to the submission of the postal ballot notice made to the exchanges on 08.01.2026, the ordinary resolution proposed to be passed by the members for appointment of Dr. Mukesh Beekamchand (DIN # 11295580) as non executive and Independent Director of the Company for a initial term of 5 years, has been passed by shareholders through postal ballot , with requisite majority..

We are submitting the following to the exchanges in compliance with the above referred regulations of SEBI.

- 1.Voting results in the prescribed format.
- 2.Report of the scrutinizer dated 09.02.2026.

The above-mentioned reports are also made available on our website [www.balpharma.com](http://www.balpharma.com) and also on the websites of the depositories.

We request you to take the same on record.

For Bal Pharma Limited

Authorized Signatory.



# BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1,  
Palace Road, Bangalore - 560 052, India.

## Annexure-1

### Voting Results of the Postal Ballot Notice dated 08.01.2026.

Voting period of postal ballot	Friday 9 <sup>th</sup> January 2026 at 9.00 A.M IST and concludes on Saturday 07 <sup>th</sup> February 2026 at 5.00 P.M IST
Number of shareholders as on the cutoff date.	15,793

To consider and if thought fit, to pass, the following Resolution as Ordinary Resolution.

**Approval for appointment of Dr. Mukesh Beekamchand (DIN 11295580) as Non Executive Independent Director of the Company, for a period of 5 (five) years.**

**“RESOLVED THAT** pursuant to the provisions of Section 161 of the Companies Act, 2013 read with the Rules relevant made thereunder and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, if any, and Articles of Association of the Company, Dr. Mukesh Beekamchand (DIN 11295580) who was appointed as an Additional Director of the Company on 12<sup>th</sup> November, 2025 by the Board of Directors of the Company based on the recommendation of the Nomination and Remuneration Committee to hold office until the date of next General Meeting or within a period of three months from the date of appointment, whichever is earlier, be and is hereby appointed as a Director of the Company in the category of Independent and Non-Executive Director.

**RESOLVED FURTHER THAT** pursuant to the provisions of Sections 149, 150 and 152 read with Schedule IV of the Companies Act, 2013 and other applicable provisions, if any, of the Companies Act, 2013 (the Act, 2013), (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and the Companies (Appointment and Qualifications of Directors) Rules, 2014, Regulations 17, 25(2A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and based on the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company, approval of the members be and is hereby accorded for the appointment of Dr. Mukesh Beekamchand (DIN 11295580), as a Non-Executive Independent Director (NE-ID) of the Company, for a period of five consecutive years i.e up to 06<sup>th</sup> February 2031, and whose office shall not be liable to retire by rotation during his tenure as NE-ID. And will be entitled to receive remuneration by way of sitting fees if any, within the permissible limit(s) and as determined by the Board, from time to time, reimbursement of expenses for participation in the meetings of the Board and / or Committees in terms of applicable provisions of the Companies Act, 2013.

**RESOLVED FURTHER THAT** the any of the Directors or the Company Secretary be and is hereby authorized to do all acts, deeds and things as may be necessary, proper or expedient to give effect to this resolution."



# BAL PHARMA LIMITED

Corporate Office

+91 80 4137 9500

info@balpharma.com

5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India.

## POSTAL BALLOT RESULTS

Resolution required (Ordinary / Special)				Ordinary				
Whether promoter / promoter group are interested in the agenda/ resolution				No				
Category	Mode of Voting	No of shares held (1)	No of votes polled (2)	% of votes polled on outstanding shares (3)={ (2)/(1)} *100	No of votes - In favour (4)	No of votes - against (5)	% of votes in favour on votes polled (6)={ (4)/(2)} *100	% of votes against on votes polled (7)={ (5)/(2)} *100
Promoter and Promoter Group	e-Voting Poll	0	0	0	0	0	0	0
	Postal Ballot	0	0	0	0	0	0	0
	Total	8097182	6450719	79.66	6450719	0	100	0
		8097182	6450719	79.66	6450719	0	100	0
Public Institutions	e-Voting Poll	0	0	0	0	0	0	0
	Postal Ballot	0	0	0	0	0	0	0
	Total	20661	20661	100	20661	0	100	0
		20661	20661	100	20661	0	100	0
Public Non Institutions	e-Voting Poll	0	0	0	0	0	0	0
	Postal Ballot	0	0	0	0	0	0	0
	Total	7803029	12463	0.16	11167	1296	89.60	10.40
		7803029	12463	0.16	11167	1296	89.60	10.40
<b>Total</b>		<b>15920872</b>	<b>6483843</b>	<b>40.72</b>	<b>6482547</b>	<b>1296</b>	<b>99.98</b>	<b>0.020</b>

For Bal Pharma Limited

Authorised Signatory



**PARAMESHWAR G. BHAT**

B.Com., LLB, ML, MBA, FCS

Company Secretary

# 496/4, II Floor, 10th Cross

Near Bashyam Circle, Sadashivanagar,  
Bangalore - 560 080

Tel : +91 80 23610847

Telefax : +91 80 41231106

e-mail : parameshwar@vjkt.in

parameshwar.g.bhat@gmail.com

## REPORT OF SCRUTINIZER ON E-VOTING AND POSTAL BALLOT PROCESS

*Private & Confidential*  
*{Strictly to the addressee only}*

09.02.2026

To

Mr. Shailesh Siroya

Managing Director

Bal Pharma Limited

(CIN: L85110KA1987PLC008368)

21 & 22, Bommasandra Industrial Area,

Bengaluru- 560099

Dear Sir

I, Parameshwar G. Bhat, Company Secretary in Whole-Time Practice (FCS No 8860, CP No.11004), having Office at # 496/4, 2<sup>nd</sup> Floor, 10<sup>th</sup> Cross, Near Bashyam Circle, Sadashivanagar, Bengaluru – 560080, was duly appointed as Scrutinizer by the Company for the purpose of scrutinizing the Postal Ballot undertaken by your Company vide Notice dated 02<sup>nd</sup> January, 2026, facility provided as per Sections 108 and 110 of the Companies Act, 2013 ('the Act'), read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 as amended from time to time ('the Rules') and various circulars issued by the Ministry of Corporate Affairs (MCA) namely, Circular No.19/2021 dated December 8, 2021 read with Circular No.14/2020 dated April 8, 2020, Circular No. 17/2020 dated April 13, 2020 and Circular No. 20/2020 dated May 5, 2020, Circular No. 02/2021 dated January 13, 2021 Circular No. 03/2022 dated May 5, 2022, General Circular No. 11/2022 dated December 28, 2022 and General Circular No. 09/2024 dated September 19, 2024 and read with other relevant circulars issued in this regard the latest being General Circular No. 03/2025 dated September 22, 2025 (collectively referred to as "MCA Circulars") and the provisions of Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

My responsibility as Scrutinizer is to ensure that the voting process is conducted in a fair and transparent manner and is restricted to make a Scrutinizer's Report for the votes casts in "favour" or "against" on the resolution proposed in the Notice dated 02<sup>nd</sup> January, 2026 based on the report provided by National Securities Depository Limited





(NSDL), the Agency engaged by the Company to provide e-voting facility up to 07<sup>th</sup> February, 2026 (5.00 P.M. IST).

In terms of the aforesaid Notice and as per the provisions of the Act and the Rules, e-voting was kept open from Friday, 09<sup>th</sup> January, 2026 (9.00 A.M. IST) till Saturday, 07<sup>th</sup> February, 2026 (5.00 P.M. IST) and Members were requested to cast their votes electronically conveying their assent or dissent in respect of the Resolution on the e-voting platform.

The details containing *inter-alia*, the list of the Members, who voted "for" or "against" on the Resolution that was put to vote, was derived from the report generated from the e-voting website of National Securities Depository Limited (NSDL) i.e. <https://evoting.nsdl.com> and based on such reports,

a. 58(Fifty Eight) members (folio wise) have cast their votes through remote e-voting.

On verification of 58 (Fifty Eight) members voting through e-Voting, up to 07<sup>th</sup> February, 2026(5.00 P.M. IST) from the Shareholders of Bal Pharma Limited, holding Equity Shares and based on the information made available to me, I hereby submit my Report on the results of the Postal Ballot, as follows:

**VOTING ANALYSIS:**

**SPECIAL BUSINESS:**

**ITEM NO. 1. APPOINTMENT OF DR. MUKESH BEEKAMCHAND (DIN – 11295580) AS NON-EXECUTIVE INDEPENDENT DIRECTOR OF THE COMPANY, FOR A PERIOD OF 5 (FIVE) YEARS:**

**ORDINARY RESOLUTION:**

Particulars	No. of votes contained in Remote E-voting		
	No. of members voted	No. of Votes cast (Shares)	% Total Valid Votes Cast
Assent	52	6482547	99.98
Dissent	6	1296	0.02
Total	58	6483843	100.00
Invalid / Abstained	NIL	NA	NA






Based on the above information, you may kindly declare the results and take steps accordingly.

Thanking you

Yours faithfully

  
Parameshwar G. Bhat  
Practicing Company Secretary  
Membership No.: 8860  
CP No.: 11004  
Scrutinizer  
Peer Review No.: 5508/2024  
UDIN: F008860G003899351

